Proton pump inhibitors , which are used to control acid reflux, are associated with an increased risk for migraine and other severe headache types, new research showed.
"It's important to note that many people do need acid-reducing medications to manage acid reflux or other conditions, and people with migraine or severe headache who are taking these drugs or supplements should talk with their doctors about whether they should continue," lead author Margaret Slavin, PhD, of the University of Maryland in College Park, said in aPrevious research has shown that headache is listed among the most common adverse reactions in adults taking PPIs and...
To compare the risk from PPIs vs H2RAs and other generic researchers analyzed data from the NHANES for those who used PPIs, H2RAs, and generic antacids to learn more about the potential link between acid-suppression therapy and headache.
Migraine Headache Proton Pump Inhibitor Proton-Pump Inhibitor Acid Suppressive Therapy PPI Headache Generics Generic Drug Generic Medication Body Mass Index BMI Diet Histamine Maryland Nutrition Prescription Drug Receptors
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
SGLT2 Inhibitors Safe and Effective in Heart Failure Related to Congenital Heart DiseaseNew research suggests that sodium-glucose transporter 2 (SGLT2) inhibitors are safe and well-tolerated in people with heart failure related to adult congenital heart disease (ACHD) and can reduce hospitalization rates. This offers hope for improved treatment options for these patients.
Source: Medscape - 🏆 386. / 55 Read more »
SGLT2 Inhibitors Safe for HF in Congenital Heart DiseaseSGLT2 inhibitors not only were safe in adult patients with congenital heart disease who develop heart failure but also were associated with reduced hospitalizations.
Source: Medscape - 🏆 386. / 55 Read more »
SGLT2 Inhibitors Reduce Anemia Risk in Concomitant T2D, CKDInitiating treatment with SGLT2 inhibitors vs GLP-1 RAs was linked to a 19% reduced risk for composite anemia outcomes in patients with T2D and CKD stages I-III.
Source: Medscape - 🏆 386. / 55 Read more »
Scientists find new ways to convert inhibitors into degraders, paving the way for future drug discoveriesResearchers have discovered ways to convert inhibitor-style targeted cancer drugs into small molecules known as degraders, which help destroy cancer-promoting proteins in cells.
Source: physorg_com - 🏆 388. / 55 Read more »
Scientists uncover key resistance mechanism to Wnt inhibitors in pancreatic and colorectal cancersA new study reveals why some pancreatic and colorectal tumors resist targeted anti-Wnt drugs and suggests how to overcome it, offering new hope to patients with fully treatment-resistant cancers.
Source: ScienceDaily - 🏆 452. / 53 Read more »
DMARD Taper to Discontinuation With Conventional Synthetics or TNF Inhibitors Increases Flare Risk in RAIn two trials, most patients with RA in remission who tapered csDMARD or TNF inhibitor drugs to withdrawal experienced flares within 3 years.
Source: Medscape - 🏆 386. / 55 Read more »